Myelosuppression and infectious complications in children with down syndrome and acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 58, Issue 4, 2012, Pages 633-635

  Rabin, Karen R ^a   Smith, Justin ^a   Kozinetz, Claudia A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

ALL; Down syndrome; Infections

Indexed keywords

ANTINEOPLASTIC AGENT; FOLINIC ACID; IMMUNOGLOBULIN; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CELLULITIS; CHILD; CONTROLLED STUDY; DOWN SYNDROME; DRUG DOSE REDUCTION; FEMALE; HOSPITALIZATION; HUMAN; LYMPHOCYTE COUNT; MALE; MONOCYTE; MONOCYTOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELLULITIS; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; FEMALE; HUMANS; INFANT; LEUKOCYTE COUNT; MALE; NEUTROPENIA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84863161182     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23371     Document Type: Article

References (21)

1. Rabin KR, Whitlock JA. Malignancy in children with trisomy 21. Oncologist 2009; 14: 164-173.
2. Whitlock JA. Down syndrome and acute lymphoblastic leukaemia. Br J Haematol 2006; 135: 595-602.
3. de la Fuente J, Richards S, Webb DK, et al. Acute lymphoblastic leukaemia has a poor outcome in children with Down Syndrome due to infective death in remission (results of UK MRC ALL 97 trial). Blood 2005; 106: 256a.
4. Maloney KW, Larsen E, Mattano LA, et al. Increased infection-related mortality for children with Down syndrome in contemporary Children's Oncology Group acute lymphoblastic leukemia clinical trials. Blood 2006; 108: 1865a.
5. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2003.
6. de Hingh YC, Van der Vossen V, Gemen EF, et al. Intrinsic abnormalities of lymphocyte counts in children with down syndrome. J Pediatr 2005; 147: 744-747.
7. Cocchi G, Mastrocola M, Capelli M, et al. Immunological patterns in young children with Down syndrome: Is there a temporal trend? Acta Paediatr 2007; 96: 1479-1482.
8. Kusters MA, Verstegen RH, Gemen EF, et al. Intrinsic defect of the immune system in children with Down syndrome: A review. Clin Exp Immunol 2009; 156: 189-193.
9. Bloemers BL, van Bleek GM, Kimpen JL, et al. Distinct abnormalities in the innate immune system of children with Down syndrome. J Pediatr 2010; 156: 804-809, 809.
10. Kivivuori SM, Rajantie J, Siimes MA. Peripheral blood cell counts in infants with Down's syndrome. Clin Genet 1996; 49: 15-19.
11. De AG, Yuen C, Palla SL, et al. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: Implications for risk stratification and future studies. Cancer 2008; 112: 407-415.
12. Rabin KR, Gramatges MM, Borowitz MJ, et al. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer in press
13. Garre ML, Relling MV, Kalwinsky D, et al. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr 1987; 111: 606-612.
14. Peeters M, Poon A. Down syndrome and leukemia: Unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr 1987; 146: 416-422.
15. Taub JW, Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer 2005; 44: 33-39.
16. Valle M, Plon SE, Rabin KR. Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia. Leuk Res 2009; 33: 336-339.
17. Shah N, Al-Ahmari A, Al-Yamani A, et al. Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome. Pediatr Blood Cancer 2009; 52: 14-19.
18. Afzal S, Ethier MC, Dupuis LL, et al. Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J 2009; 28: 1064-1068.
19. Gamis AS, Woods WG, Alonzo TA, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: A report from the Children's Cancer Group Study 2891. J Clin Oncol 2003; 21: 3415-3422.
20. Schepis C, Barone C, Siragusa M, et al. An updated survey on skin conditions in Down syndrome. Dermatology 2002; 205: 234-238.
21. Milstone AM, Passaretti CL, Perl TM. Chlorhexidine: Expanding the armamentarium for infection control and prevention. Clin Infect Dis 2008; 46: 274-281.